Inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid carcinomas: Prognostic significance and clinical implications

被引:27
作者
Mylonas, Ioannis [1 ]
机构
[1] Univ Munich, Dept Obstet & Gynecol 1, D-80337 Munich, Germany
关键词
Endometrial cancer; Non-endometrioid carcinomas; Immunohistochemistry; Inhibin-subunits; Prognosis; Survival; TUMOR-SUPPRESSOR; CELL-PROLIFERATION; DOWN-REGULATION; ACTIVIN-A; CANCER; EXPRESSION; GROWTH; SURVIVAL; METASTASIS; PATHOLOGY;
D O I
10.1016/j.ejca.2010.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibins, dimeric peptide hormones composed of an alpha-subunit and one of two possible beta-subunits (betaA or betaB), exhibit substantial roles in human reproduction and in endocrine-responsive tumours. However, the prognostic significance and clinical implications of the inhibin-alpha, -betaA and -betaB subunits in uterine non-endometrioid cancers are still quite unclear. A series of 41 uterine non-endometrioid carcinomas were immunohistochemically analysed with monoclonal antibodies against inhibin-subunits. The staining reactions were correlated with several clinicopathological characteristics and clinical outcome. The inhibin-alpha subunit showed a significant association with age although the loss of this subunit did not affect the survival of patients with non-endometrioid carcinomas and did not constitute an independent prognostic parameter. The inhibin-betaA expression was not associated with any of the analysed clinicopathological parameters and did not affect patients' survival. In contrast, a low betaB-subunit demonstrated a significant better cause-specific survival. Moreover, inhibin-beta B did constitute an independent prognostic parameter in uterine non-endometrioid cancer patients. In contrast to inhibin-alpha and -betaA subunits, the inhibin-betaB subunit seems to have a substantial role in the carcinogenesis and pathology of uterine non-endometrioid carcinomas and might be used as a marker to identify high-risk patients and may aid in the selection of patients for a more aggressive adjuvant therapy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2485 / 2493
页数:9
相关论文
共 49 条
[1]   Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo [J].
Adkins, HB ;
Bianco, C ;
Schiffer, SG ;
Rayhorn, P ;
Zafari, M ;
Cheung, AE ;
Orozco, O ;
Olson, D ;
De Luca, A ;
Chen, LL ;
Miatkowski, K ;
Benjamin, C ;
Normanno, N ;
Williams, KP ;
Jarpe, M ;
LePage, D ;
Salomon, D ;
Sanicola, M .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (04) :575-587
[2]   Endometrial cancer [J].
Amant, F ;
Moerman, P ;
Neven, P ;
Timmerman, D ;
Van Limbergen, E ;
Vergote, I .
LANCET, 2005, 366 (9484) :491-505
[3]  
[Anonymous], 1989, GYNECOL ONCOL, V35, P125, DOI DOI 10.1016/0090-8258(89)90027-9
[4]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[5]   A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse [J].
Nolan, PM ;
Peters, J ;
Strivens, M ;
Rogers, D ;
Hagan, J ;
Spurr, N ;
Gray, IC ;
Vizor, L ;
Brooker, D ;
Whitehill, E ;
Washbourne, R ;
Hough, T ;
Greenaway, S ;
Hewitt, M ;
Liu, XH ;
McCormack, S ;
Pickford, K ;
Selley, R ;
Wells, C ;
Tymowska-Lalanne, Z ;
Roby, P ;
Glenister, P ;
Thornton, C ;
Thaung, C ;
Stevenson, JA ;
Arkell, R ;
Mburu, P ;
Hardisty, R ;
Kiernan, A ;
Erven, H ;
Steel, KP ;
Voegeling, S ;
Guenet, JL ;
Nickols, C ;
Sadri, R ;
Naase, M ;
Isaacs, A ;
Davies, K ;
Browne, M ;
Fisher, EMC ;
Martin, J ;
Rastan, S ;
Brown, SDM ;
Hunter, J .
NATURE GENETICS, 2000, 25 (04) :440-443
[6]   Activin and estrogen crosstalk regulates transcription in human breast cancer cells [J].
Burdette, Joanna E. ;
Woodruff, Teresa K. .
ENDOCRINE-RELATED CANCER, 2007, 14 (03) :679-689
[7]   Non-endometrioid carcinomas of the uterine corpus: A review of their pathology with emphasis on recent advances and problematic aspects [J].
Clement, PB ;
Young, RH .
ADVANCES IN ANATOMIC PATHOLOGY, 2004, 11 (03) :117-142
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237
[10]   Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17β-estradiol [J].
Di Simone, N ;
Schneyer, AL ;
Caliandro, D ;
Castellani, R ;
Caruso, A .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 192 (1-2) :187-195